Acema

Quick links to important sections

Acema

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acema

What is Acema?

Acema is a pharmaceutical formulation containing the active ingredient acemetacin. It belongs to a group of medications known as non-steroidal anti-inflammatory drugs (NSAIDs). These medications are primarily used to manage symptoms associated with inflammation and pain.

Mechanism of Action

Acemetacin is a glycolic acid ester of indometacin. Once ingested, it acts as a prodrug, meaning it is metabolized within the body to form indometacin, alongside other metabolites. This process allows the medication to inhibit the activity of enzymes known as cyclooxygenases (COX-1 and COX-2). These enzymes play a central role in the production of prostaglandins, which are chemicals in the body that signal pain and promote inflammation.

By reducing the concentration of prostaglandins in affected tissues, Acema helps to decrease swelling, redness, and physical discomfort.

Therapeutic Use

Acema is used to address various conditions characterized by acute or chronic inflammation. It is most commonly employed in the management of joint and muscular disorders. These may include:

  • Rheumatoid arthritis: A chronic inflammatory condition affecting the joints.
  • Osteoarthritis: A degenerative joint disease.
  • Ankylosing spondylitis: A type of arthritis that primarily affects the spine.
  • Acute gout: A condition involving sudden, severe attacks of pain and tenderness in the joints.
  • Post-operative inflammation: Swelling and pain following surgical procedures.
  • Lower back pain: General inflammatory discomfort in the lumbar region.

Pharmacological Characteristics

As an NSAID, Acema is designed to provide symptomatic relief. It does not cure the underlying cause of inflammatory diseases but assists in improving mobility and reducing the intensity of pain during flare-ups or chronic management phases. The absorption and metabolism of acemetacin are designed to provide a steady release of the active metabolite, aiming for a sustained therapeutic effect.

Regulatory References

  1. opioid analgesic
  2. dual action
  3. mu-opioid receptors
  4. norepinephrine and serotonin

What side effects are possible with Acema?

Possible Side Effects and Safety Information

The safety profile of Acema (Tramadol Hydrochloride) is defined by categories of adverse reactions and specific warnings documented in official regulatory sources. These effects are often grouped by the body system affected, known as System-Organ Classes.

Regulatory Classification of Adverse Reactions

The most frequently reported adverse reactions, categorized as Very Common (occurring in ge 10% of patients in clinical trials), include nausea, dizziness or vertigo, and constipation. Other common effects include headache, somnolence, vomiting, dry mouth, pruritus, and sweating. These effects primarily involve the Gastrointestinal and Nervous Systems and are often reported more frequently during the initial treatment phase.

Serious Adverse Reactions and Safety Constraints

Official labeling mandates warnings regarding serious, potentially life-threatening risks. A primary concern is Life-Threatening Respiratory Depression, with the risk noted to be highest during treatment initiation or following a dose increase. The medication may also increase the risk of seizures and is associated with the potentially life-threatening condition known as Serotonin Syndrome.

Use is further restricted for certain patient populations. The medicine is contraindicated in children younger than 12 years of age and in adolescents under 18 following specific surgical procedures. Increased caution is required for older adults and individuals with severe hepatic or renal impairment due to altered drug clearance. Prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome.

Overdose and Emergency Response

The official documentation for Acema (Tramadol) overdose describes critical, life-threatening manifestations that necessitate immediate emergency action. Overdose may present with severe Central Nervous System (CNS) depression, leading to states of confusion, profound somnolence, and coma. Neurological risks include the occurrence of seizures (convulsions) and the potentially fatal complication of Serotonin Syndrome. The most severe outcomes documented include life-threatening respiratory depression, which can progress rapidly to respiratory arrest, cardiovascular collapse, and death.

Regulatory authorities mandate that immediate medical attention be sought for any suspected overdose. Specific emergency actions detailed in the labeling include the administration of Naloxone to manage the opioid-induced respiratory depression and the use of diazepam to control convulsions. Procedures such as gastric lavage and general supportive measures to maintain respiratory and circulatory function are officially described.

A specific warning exists regarding children, for whom accidental ingestion of even a single dose constitutes a life-threatening scenario requiring urgent emergency contact. Monitoring requirements include taking a blood sample for drug concentration and performing necessary hepatic tests. Patients with ultra-rapid metabolism or pre-existing respiratory issues are documented as having an increased risk of life-threatening respiratory depression.

Therapeutic Uses of Acema

What Acema Treats: Main Uses and Benefits

Acema is used for the management of symptoms related to physical discomfort that may be severe enough to warrant consideration of an opioid analgesic, and for which alternative treatments may be inadequate.


Managing Moderate to Moderately Severe Pain

Acema is used for systemic pain management when physical discomfort is classified as moderate to moderately severe, meaning the intensity interferes with daily functioning and comfort. This application is relevant when generalized pain is pronounced, and supports the easing of physical discomfort during symptomatic periods in adult patients. It is commonly applied in scenarios requiring long-term symptom management associated with chronic conditions, such as osteoarthritis and certain neuropathic disorders, as well as in short-term, acute pain episodes like those experienced in the post-operative setting.

Benefits for Symptom Intensity and Comfort

This medication is relevant when discomfort is pronounced, and it plays a role in managing symptoms that appear suddenly or are persistent. The core benefit is that Acema supports general well-being during symptomatic phases and provides support that helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods.

Quick Fact: Relief for Persistent and Acute Discomfort

Regulatory References

  1. U.S. Food and Drug Administration

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Acema

The eligibility for Acema (Tramadol) is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status. The medication is primarily intended for use by adults (generally 18 years and older) who require an opioid analgesic for moderate to moderately severe pain.

Population Group Regulatory Status
Children under 12 years Contraindicated
Adolescents under 18 (post-tonsillectomy/adenoidectomy) Contraindicated
Patients on MAOIs (or within 14 days of use) Contraindicated
Severe Respiratory Depression Contraindicated

Use of Acema is not recommended in several high-risk populations. This includes patients with severe hepatic impairment or severe renal impairment (creatinine clearance <30 mL/min), as delayed drug elimination may increase risk. Patients identified as ultra-rapid metabolizers are also advised against use due to the risk of life-threatening toxicity. Additionally, use is generally not recommended during pregnancy or lactation, as prolonged exposure during pregnancy can result in neonatal opioid withdrawal syndrome. Older adults (over 75 years) require special consideration due to potential prolongation of drug elimination.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Acema (Tramadol) is officially defined by regulatory bodies through pharmacokinetic and pharmacodynamic mechanisms that lead to specific restrictions and prohibitions.

Pharmacodynamic and Contraindicated Interactions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the high risk of Serotonin Syndrome and opioid toxicity. Regulatory labeling specifies that a mandatory 14-day separation period is required after discontinuing an MAOI before starting Acema. A similar elevated risk of Serotonin Syndrome exists with other serotonergic drugs (e.g., SSRIs, SNRIs). Co-use with CNS depressants, including alcohol and medications like benzodiazepines, is restricted because of an additive effect, increasing the risk of profound sedation and respiratory depression. Interactions with Coumarin derivatives (e.g., Warfarin) have been reported to alter anticoagulant effect.

Pharmacokinetic Interactions

The metabolism of Acema involves the CYP2D6 and CYP3A4 enzymes, which is the basis for several documented pharmacokinetic interactions. Substances that inhibit CYP2D6 (e.g., quinidine) may increase the drug's concentration while reducing the active metabolite (M1) level. Conversely, CYP3A4 inducers, such as Carbamazepine, are documented to significantly reduce Tramadol exposure, which may diminish its analgesic efficacy. Regulatory notes indicate that use is not recommended in breastfeeding women due to the risk of exposing the infant to life-threatening M1 metabolite levels, particularly if the mother is a CYP2D6 ultra-rapid metabolizer.

Mechanism of Action

Acema functions as an aryl hydrocarbon receptor (AHR) agonist, targeting intracellular AHRs predominantly within epidermal keratinocytes of the skin. Upon binding, Acema activates the AHR, initiating a signaling cascade that modifies gene transcription.

This interaction upregulates the expression of key structural proteins, specifically filaggrin and related barrier components, promoting the differentiation of keratinocytes. Concurrently, the activation of AHR leads to the dephosphorylation of Signal Transducer and Activator of Transcription 6 (STAT6). This dephosphorylation event interferes with the signaling pathway activated by the T helper 2 (Th2) cytokines, such as Interleukin-4 (IL-4) and Interleukin-13 (IL-13). The subsequent inhibition of Th2 cytokine signaling results in a downstream reduction of inflammatory mediators and the associated repression of epidermal differentiation. The overall systemic physiological consequence involves the stabilization of the epidermal barrier function and a modulation of cutaneous immune signaling.

Dosage and Administration Information

How Acema is Used: Official Dosing and Administration

The usage of Acema (Tramadol) is defined by its administration route, dosage form, and specific dosing patterns established for clinical use. This guidance dictates how the medicine should be administered to manage moderate to moderately severe pain.


Administration Routes and Forms

Acema is administered through the oral route via tablets, capsules, or solutions, and through the parenteral route via injection or infusion in clinical settings. The medicine is available as Immediate-Release (IR) forms, typically dosed every four to six hours, and Extended-Release (ER) forms, which are administered once daily for continuous symptom management.


Standard Dosing and Use Conditions

Usage Constraint Official Labeling Detail
Maximum Daily Dose (IR) Generally 400 mg/day for adults, or 300 mg/day for adults over 75 years.
IR Dosing Frequency Administered as needed, typically every four to six hours, not to exceed the maximum daily limit.
Proper Intake Oral forms can usually be taken without regard to meals. Extended-Release tablets or capsules must be swallowed whole and must not be crushed, chewed, or split.
Renal/Hepatic Impairment Dosing intervals are typically extended (e.g., to 12 hours) and the total daily dose is reduced for patients with moderate to severe impairment.
Discontinuation When treatment ends, Acema must be tapered gradually to prevent the occurrence of withdrawal symptoms.

High-Level Procedural Structure

The official protocol mandates starting at the lowest effective dose and using the medicine for the shortest duration necessary, with continuous re-evaluation of the need for continued administration. The distinct schedules for IR (as-needed) and ER (daily) forms structure how the medicine is used over time, and adjustments are explicitly required for certain populations to align with safety profiles.

Recent Clinical Evidence

Research evidence / Overview of studies for Acema

The research base for Acema (tramadol) consists primarily of randomized controlled trials (RCTs) and systematic reviews, which contribute to the research structure for evaluating patient-reported experiences in various research contexts. This research helps provide context on what has been observed so far in specific patient groups under controlled conditions.


Evidence for Use in Acute Postoperative Pain

This area of research has focused on temporary physiological imbalance in patients experiencing outcomes related to acute changes, specifically after surgery. Short-term RCTs were conducted during periods of increased symptom activity, observing patient-reported outcomes describing perceived discomfort over a defined time interval. These studies monitored outcomes related to physical discomfort, such as the need for rescue pain medication. Research highlights changes measured during the study period, with some meta-analyses indicating that the use of Acema was associated with a reduced need for other pain medication in the immediate 24- to 48-hour recovery phase. Follow-up durations were limited, typically not exceeding 48 hours, providing limited insight into long-term post-surgical outcomes.


Evidence for Use in Chronic Pain Conditions

Acema was studied for its application in trials assessing short-term or episodic symptom patterns related to general chronic, non-cancer pain, which are conditions marked by functional limitations. The studies examined changes in patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies where some trials indicated a measurable change in pain intensity compared to placebo. However, evidence certainty remains low; reviewers noted that while a measured change was observed, the difference was small and may not have reached a threshold considered a significant improvement by patients. There is limited information for long-term outcomes, as the follow-up durations typically spanned only 4 to 12 weeks.


Key Gaps and Remaining Research Uncertainty

The broader evidence landscape highlights areas where more research is needed. Reviewers of the research describe that the certainty remains low across multiple indications due to small sample sizes and the heterogeneity of chronic pain groups. Furthermore, evidence is limited regarding studies comparing treatments across longer durations. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Tramadol Hydrochloride Extended Release Tablets - Official FDA Labeling
  2. Tramadol: Clinical Pharmacology, Mechanism of Action, and Indications - NIH StatPearls

Frequently Asked Questions (FAQ)

Common questions about Acema (FAQ)

Q: How quickly does Acema typically start to work after I begin taking it?

A: According to official product information, the pain-relieving effects from immediate-release forms of Acema typically begin in about one hour. The medication generally reaches its peak effectiveness approximately two to three hours after it is taken by mouth.


Q: How long does the effect of one dose of Acema last?

A: Studies and official information indicate that the analgesic effect of one dose of the immediate-release form of Acema lasts for approximately six hours. This duration aligns with the established interval for immediate-release forms to manage symptoms.


Q: Are there any specific foods or drinks that should be avoided while on Acema?

A: Official regulatory warnings state that alcohol consumption should be avoided while taking Acema, as this combination may increase the risk of severe side effects, including extreme drowsiness and life-threatening breathing problems. The oral forms of Acema can generally be taken with or without food.


Q: How long can a person usually stay on Acema treatment?

A: The official protocol recommends using the lowest effective dosage for the shortest duration that is consistent with the goals of treatment. Continued use is subject to the established protocol of re-evaluating the ongoing need for treatment. Regulatory guidance focuses on continuous assessment rather than setting a specific maximum treatment time.


Q: Are there any known long-term side effects associated with Acema?

A: Regulatory documents list adverse reactions observed in clinical trials and postmarketing surveillance. Prolonged use of Acema may lead to the development of physical dependence. When the medication is discontinued, physical dependence may be accompanied by withdrawal symptoms.


Q: How is Acema stored, and what happens if it gets too hot or cold?

A: Official labeling states that Acema must be kept at a Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from both light and moisture. The official instructions explicitly warn that the medication must not be frozen.


Q: Is it normal for Acema to cause mild stomach upset when starting out?

A: Regulatory documents classify nausea and vomiting as common adverse reactions reported in clinical trials. These effects often occur more frequently during the initial period of treatment as the body adjusts to the medication. This experience may be interpreted by patients as general stomach upset.


Q: How long does it take for Acema to be fully cleared from the body?

A: According to official pharmacokinetic data, the average time it takes for half of the dose to be eliminated (half-life) is about 6.3 hours for Acema itself. For the active pain-relieving part of the medicine, this half-life is approximately 7.4 hours. Elimination occurs mainly through metabolism by the liver and excretion by the kidneys.


Q: Will taking Acema impact my ability to drive or operate machinery?

A: Official patient counseling information warns that Acema can impair the mental and physical abilities needed to perform potentially hazardous tasks. These tasks include driving a car or operating heavy machinery. Regulatory warnings state that individuals should refrain from these activities until they have experience with the medication’s effects.


Q: Can men and women expect different results or side effects from Acema?

A: Pharmacokinetic studies have noted some small differences in the concentration of the medication in the body between males and females. However, the clinical significance of this observed difference is currently unknown, and regulatory documents do not provide separate expectations for general side effects based on gender.


Q: Is it necessary to have routine blood work done while taking Acema?

A: Official guidance does not universally mandate routine blood work for all patients. However, close monitoring for conditions like hyponatremia (low sodium levels) and hypotension (low blood pressure) is mentioned. Increased monitoring for these conditions may be recommended for some patients.


Q: Can Acema affect fertility in men or women?

A: Studies noted in regulatory documents indicate that chronic or long-term use of this class of medication may cause reduced fertility in both men and women of reproductive potential. It is currently not known if these effects on fertility are permanent or reversible.


Q: Are there specific times of day that are best for taking Acema?

A: The best time depends on the type of Acema used. Immediate-release forms are taken as needed for pain. Extended-release forms are typically administered once daily at the same time each day to help maintain consistent levels of the medicine in the body.


Q: Does Acema have a history of recalls or safety warnings?

A: Regulatory labeling includes specific warnings, such as a prominent Boxed Warning, to highlight serious risks associated with the medication. These risks include the potential for addiction, abuse, misuse, and life-threatening respiratory depression (severe slowing of breathing).


Q: Is Acema known to cause sun sensitivity or skin reactions?

A: Official postmarketing surveillance reports have included instances of serious skin reactions. These reports include conditions like Toxic Epidermal Necrolysis and Stevens Johnson syndrome, as well as less severe allergic reactions such as hives and generalized itching.

How should Acema be stored and disposed of?

How to Store and Dispose of Acema

Acema (Tramadol) must be stored strictly according to regulatory specifications to ensure stability and safety. The medicine should be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C.

It is required to keep the product in a tight container, protected from both light and moisture, and away from heat. The medicine must not be frozen.

Handling and Disposal

Due to its classification as a controlled substance, official labeling mandates that Acema must be stored out of the reach of children to prevent accidental ingestion. For disposal of unused or expired product, patients are advised to utilize official Drug Take-Back Options or follow specific household trash procedures established by the FDA, ensuring the medicine is not accessible to others.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Acema found in:

A-Z Index: